

## Virulence Factor Profile and Biofilm Formation Ability of *Acinetobacter baumannii* Strains Isolated from Hospitalized Patients

SAMIRA JAHANGIRI<sup>1</sup>, MOHAMMAD MOTAMEDIFAR<sup>1,2\*</sup>, NAHAL HADI<sup>1</sup>

<sup>1</sup>Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>2</sup>Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence to Dr. Mohammad Motamedifar, Email: [motamedm@sums.ac.ir](mailto:motamedm@sums.ac.ir), Tel/Fax: + (98) 71 3230 4356.

### ABSTRACT

**Background:** *Acinetobacter baumannii* is an opportunistic pathogen which plays crucial roles in nosocomial infections and hospital outbreaks.

**Aim:** To investigate to determine the presence of virulence factors and the ability of biofilm production by isolated *A. baumannii* from hospitalized patients.

**Methods:** The prevalence of *A. baumannii* in clinical samples was identified with standard biochemical tests. Polymerase chain reaction (PCR) was used for investigation of the presence of virulence factors in isolated strains.

**Results:** Isolates were assayed for biofilm formation by microtiter plate method. Of 120 samples, 100 (83.33%) were positive for *A. baumannii*. Although the presence of *iutA* (10%) and *papC* (5%) virulence genes was confirmed by PCR, isolated *A. baumannii* were negative for *cnf1*, *cnf2*, *fnb*, and *kpsMT II* virulence factors. Moreover, the quantification of biofilm production showed that 61% of the isolates were able to produce biofilm ( $P=0.028$ ). Also, there was no relationship between the presence of *iutA* and *papC* genes and biofilm formation. The significant rates of *A. baumannii* isolates were able to form biofilm which could lead to their survival in a hospital environment.

**Conclusion:** Iron uptake and fimbriae could be considered as important virulence factors in survival and adherence of *A. baumannii*.

**Keyword:** *Acinetobacter baumannii*, Polymerase chain reaction, Biofilm, *iutA*, *papC*

### INTRODUCTION

One of the most causes of mortality and morbidity worldwide is hospital-associated infections (HAIs). Among the reasons for HAIs, bacteria play an important role, and *Acinetobacter baumannii* is one of the most predominant bacteria leading to HAIs<sup>1</sup>. *A. baumannii* is an opportunistic pathogen which causes a wide range of infections including pneumonia<sup>2</sup>, bacteremia<sup>3</sup>, urinary tract infections<sup>4</sup>, wound infections<sup>5</sup> and meningitis<sup>6</sup>. These hospital outbreaks are due to the ability of *A. baumannii* to survive in the hospital environment and to resistance to various antibiotics<sup>7</sup>. There are several factors contributing to the success of *A. baumannii* in survival in the hospital environment: (i) ability to form biofilm and adhere to biotic and abiotic surfaces such as environmental surfaces and medical devices<sup>8</sup>; (ii) ability to adhere to, colonize, and invade epithelial cells<sup>9,10</sup>; (iii) ability to obtain foreign genetic materials to enhance its survival under host selection pressures and antibiotic treatment<sup>11,12</sup> and (iv) its specific mechanisms of antibiotic resistance<sup>7</sup>. Among the mentioned factors, biofilm formation is the primary factor involved in bacterial resistance and survival<sup>13</sup>. Biofilm is a complex mixture of bacteria which is often enclosed with thick polysaccharide layer and is responsible for resistance to antibiotics<sup>14,15</sup>. There are several virulence determinants which are associated with biofilm formation of *A. baumannii*. The present study was done to investigate the presence of various virulence factors and biofilm formation by clinical isolates of *A. baumannii*.

### MATERIALS AND METHODS

**Sample collection and identification of *A. baumannii*:** In this study, a total of 120 clinical samples were collected from Namazi hospital in Shiraz, Iran. All *A. baumannii* isolates were isolated

from ICU (n=81), internal (n=30), and transplantation wards (n=9). The samples were transferred to brain-heart infusion broth medium and incubated aerobically for 24 h at 37°C. The turbid broth of the specimens was plated on blood agar (Merck, Germany) and MacConkey (Merck, Germany) for standard aerobic growth. Non-hemolytic and opaque colonies on blood agar and non-lactose fermentative colonies on MacConkey were subcultured on MacConkey agar and incubated for another 24h at 37°C to obtain pure colonies. *A. baumannii* species were identified by microscopic characteristics, Gram stain, and biochemical tests including IMVIC, catalase, urease, and oxidase. *A. baumannii* was confirmed using *bla*<sub>OXA-51-like</sub> PCR assay<sup>16</sup>.

**Detection of biofilm formation:** Biofilm formation was assessed by microtiter plate method. For biofilm development, *A. baumannii* cultures were inoculated in trypticase soy broth (TSB) (Merck, Germany) with 20% glucose and adjusted to 0.5 McFarland standards. Each well of sterile 96-well polystyrene microtiter plates was filled with 200µl of bacterial suspension. The plates were aerobically incubated overnight at 37°C. Afterwards, the wells were tenderly washed three times with phosphate buffered saline (PBS) and stained for 5 min with 2% crystal violet. Excess crystal violet was rinsed off by water and

then air-dried. To resolubilize the dye bounded to the adherent cells, we the wells with 200µl of 33% glacial acetic acid. The optical density (OD) was measured at 570 nm, using ELISA reader. The OD results were grouped for biofilm formation as follows: (I) OD < 0.5 = non-biofilm producer; (II) 0.5 < OD < 1.5 = moderate biofilm producer; and (III) OD > 1.5 = strong biofilm producer.

**Detection of virulence genes by PCR:** Boiling method was used for the extraction of bacterial DNA from the isolates; the primer sequences are shown in Table 1. Polymerase chain reaction (PCR) was performed in a total volume of 25µl reaction

containing 5µl of genomic DNA, 20 pmol of each of the primers, 200µM of each dNTP, PCR buffer with 2.5 mM of MgCl<sub>2</sub>, and 1.5 U of Taq DNA polymerase (Sinaclon). The PCR condition was as follows: 5 min of the first denaturation at 94°C followed by 25 cycles of denaturation at 94°C for 30 sec, annealing at 63°C for 30 sec, extension at 72°C for 45 sec, and a final extension at 72°C for 10 min. PCR products were electrophoresed in 1.5% agarose gels containing safe DNA stain.. **Statistical analysis:** SPSS 25.0 was used for statistical analysis. The Chi-square test and Fisher’s exact 2-tailed test were performed for analysis of the data. Statistical significance was considered as <0.05.

**RESULTS**

Of the 120 clinical specimens, 100 *A. baumannii* were isolated (83.33%). All *A. baumannii* isolates were identified with

microscopic characteristics. Among the 100 *A. baumannii*, 52 of the isolates were from male patients and 48 from female patients. Presence of virulence factors was investigated by PCR assay. All isolates were analyzed for the presence of virulence genes; 10 (10%) had *iutA* gene and 5 (5%) had *papC* gene. Figure 1 illustrates the appearance of *iutA* and *papC*. However, *A. baumannii* isolates were negative for *cnf1*, *cnf2*, *fbn*, *kpsMT II* virulence factor genes.

Biofilm formation assay by microtiter plate method revealed 58% (n=58) of the isolates as biofilm producer, while 2(3%) of the isolates displayed strong biofilm formation, and 39% (n=39) indicated weak or no biofilm formation. In this study, the frequency of biofilm formation was significantly higher than the negative isolates (P=0.028). Table 2 presents the relationship between the presence of *iutA* and *papC* virulence factor genes and biofilm formation.

Fig 1; Patterns of agarose gel for detection of the virulence genes. Lane M: 100 bp ladder (Sinaclon), Lane C-: Negative control, Lane C+: Positive samples for *iutA* gene and *papC* gene, S: positive controls for *iutA* gene and *papC* gene




Table 1: Primers to virulence factor genes utilized in PCR

Gene	Virulence Factor	Primer	Sequence (5'-3')	Amplified DNA (bp)
<i>cnf1</i>	cytotoxic necrotizing factor	F	AAGATGGAGTTTCCTATGCAGGAG	498
		R	TTCAGAGTCCTGCCCTCATTATT	
<i>cnf2</i>	cytotoxic necrotizing factor	F	AATCTAATTAAGAGAAAC	543
		R	CATGCTTTGTATATCTA	
<i>fbn</i>	fibronectin receptor	F	GGTAATCAGTCATTCGAG	207
		R	TGGCACACTGTCGAAGTC	
<i>iutA</i>	aerobactin	F	GGCTGGACATCATGGGAAGTGG	300
		R	CGTCGGGAACGGGTAGAATCG	
<i>kpsMT II</i>	capsule	F	GCGCATTTGCTGATACTGTTG	272
		R	TCCAGACGATAAGCATGAGCA	
<i>papC</i>	P fimbriae	F	GACGGCTGTACTGCAGGGTGTGGCG	328
		R	TCCTTTCTGCAGGGATGCAATA	

Total	11(11%)	89(89%)	5(5%)	95(95%)
P value`	0.957		0.401	

Table 2: The relationship between the presence of virulence factor genes and biofilm formation

Biofilm	<i>iutA</i>		<i>papC</i>	
	+ve	-ve	+ve	-ve
Negative	4(10.26%)	35(89.74%)	3(7.70%)	36(92.30%)`
Moderate	7(12.06%)	51(87.94%)	2(3.34%)	56(96.55%)
Strong	0	3(100%)	0	3(100%_

**DISCUSSION**

HAIs (nosocomial infections) are known as the primary cause of death worldwide and the most important reason for nosocomial infections is Gram-negative bacteria<sup>17</sup>. *A. baumannii*, a Gram-negative bacteria, is an opportunistic pathogen which leads to

hospital outbreaks of infection due to multidrug resistance (MDR)<sup>18</sup>. Furthermore, the ability to adhere to biotic and abiotic surfaces and induce poor inflammatory responses in human cells are the other factors involved in the clinical success of *A. baumannii*<sup>19</sup>. Adhered cells could form biofilms, and biofilm increases the longevity of *A. baumannii* in hospital environments<sup>20</sup>. The current study examined the presence of virulence factors in the isolated *A. baumannii* strains from three different wards of Namazi hospital in Shiraz, Iran. The ability of biofilm formation was also investigated.

We found that 83.33% of the samples were positive for *A. baumannii*. In agreement with our results, Pourhajibagher *et al.* showed that 83.3% of the samples from burned patients were positive for *A. baumannii*<sup>21</sup>. Momtaz *et al.* reported that 24.2% of their clinical samples in Iran were positive for *A. baumannii*<sup>22</sup>. Siau *et al.* reported 11% positive *A. baumannii* for the samples in the Hong Kong hospitals<sup>23</sup>. In a study conducted in Iraq, the prevalence rate of *A. baumannii* was 18.75%<sup>24</sup>. These differences in the prevalence rate of *A. baumannii* in different studies could be associated with various factors including the differences in the number of collected samples, a method of sampling, the ward of sampling, the type of samples, geographical areas, patients, age, and sex.

Our results showed that among the virulence factors, *iutA* (10%) and *papC* (5%) genes were detected in the isolated *A. baumannii* strains. These genes are primarily associated with iron uptake and adherence. Momtaz *et al.* found that the prevalence rates of *iutA* and *papC* virulence genes were 19.00% and 7.43%, respectively, which were slightly higher than our results. In contrast to our study, they reported the high prevalence of *cnfI* (35.53%), *cnf2* (25.61%), and *kpsMT II* (14.04%) virulence genes<sup>22</sup>. In a study by Darvishi, *cnfI* and *iutA* genes were positive in 50% and 25% of *A. baumannii* isolates from hospitalized patients in healthcare centers and hospitals of Iran, respectively<sup>25</sup>. Similarly, AL-Kadmy *et al.* reported that the prevalence rates of *cnfI* and *iutA* genes in the *A. baumannii* isolates were 23.80% and 47.6%, respectively<sup>24</sup>.

Among the one hundred isolated *A. baumannii*, 61 (61%) were able to form biofilm. Likewise, other studies showed that 62%<sup>26</sup> and 63%<sup>27</sup> of the isolated *A. baumannii* produced biofilm. Dehbalaei *et al.*'s study found that 72.91% of the isolated *A. baumannii* were able to form biofilm<sup>28</sup>, which is higher than our results. Various results in biofilm production could be due to different methods. Adi-Ali *et al.* have used modified microtiter plate and test tube methods for assessment of biofilm formation. The obtained results of microtiter plate method were as follows: 25% negative, 41% weak, 10% moderate, and 18% strong. The results of the test tube were as follows: 18% negative, 42% weak, 18% moderate, and 22% strong<sup>29</sup>.

## CONCLUSION

In conclusion, we identified the high prevalence of *A. baumannii* isolated from Namazi hospital in Shiraz, Iran. Our findings revealed that *iutA* and *papC* virulence genes which are associated with iron uptake and fimbriae were positive among the isolates. We found that a large number of isolated *A. baumannii* can form biofilms which could guarantee their survival in hospital environment.

**Acknowledgements:** This study was supported by Shiraz University of Medical Sciences with grant No. 96-16197. We

would like to thank all the participants and staff at the studied hospital for their kind cooperation. This article was extracted from the MSc. thesis by S. Jahangiri under the supervision of Dr. M. Motamedifar. The authors also wish to thank the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for English editing of this manuscript.

**Conflicts of interest: none**

## REFERENCES

1. Alsan, M. and M. Klompas, *Acinetobacter baumannii: an emerging and important pathogen*. Journal of clinical outcomes management: JCOM, 2010. **17**(8): p. 363.
2. Chaari, A., et al., *Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors*. International Journal of Infectious Diseases, 2013. **17**(12): p. e1225-e1228.
3. Cisneros, J.M., et al., *Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognosis features*. Clinical infectious diseases, 1996. **22**(6): p. 1026-1032.
4. Weinstein, R.A., et al., *Overview of nosocomial infections caused by gram-negative bacilli*. Clinical infectious diseases, 2005. **41**(6): p. 848-854.
5. Guerrero, D.M., et al., *Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease*. Surgical infections, 2010. **11**(1): p. 49-57.
6. Yang, M., Z. Hu, and F. Hu, *Nosocomial meningitis caused by Acinetobacter baumannii: risk factors and their impact on patient outcomes and treatments*. Future microbiology, 2012. **7**(6): p. 787-793.
7. Cerqueira, G.M. and A.Y. Peleg, *Insights into Acinetobacter baumannii pathogenicity*. IUBMB life, 2011. **63**(12): p. 1055-1060.
8. Longo, F., C. Vuotto, and G. Donelli, *Biofilm formation in Acinetobacter baumannii*. New Microbiol, 2014. **37**(2): p. 119-127.
9. Lee, J.C., et al., *Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells*. Research in microbiology, 2006. **157**(4): p. 360-366.
10. Lee, H.W., et al., *Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces*. Clinical microbiology and infection, 2008. **14**(1): p. 49-54.
11. Smith, M.G., et al., *New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis*. Genes & development, 2007. **21**(5): p. 601-614.
12. Adams, M.D., et al., *Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii*. Journal of bacteriology, 2008. **190**(24): p. 8053-8064.
13. Thummeepak, R., et al., *Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clinical isolates*. International Microbiology, 2016. **19**(2): p. 121-129.
14. Magiorakos, A.P., et al., *Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance*. Clinical microbiology and infection, 2012. **18**(3): p. 268-281.
15. M'hamedi, I., et al., *Biofilm formation by Acinetobacter baumannii isolated from medical devices at the intensive care unit of the University Hospital of Tlemcen (Algeria)*. African Journal of Microbiology Research, 2014. **8**(3): p. 270-276.
16. Kooti, S., M. Motamedifar, and J. Sarvari, *Antibiotic resistance profile and distribution of oxacillinase genes among clinical isolates of Acinetobacter baumannii in Shiraz teaching hospitals, 2012-2013*. Jundishapur journal of microbiology, 2015. **8**(8).
17. NANDI, D. and A. ARJUNA, *ACINETOBACTER MAIN CAUSE OF HOSPITAL ACQUIRED INFECTIONS: A REVIEW*. Asian J Pharm Clin Res, 2017. **10**(5): p. 53-56.

18. Peleg, A.Y., H. Seifert, and D.L. Paterson, *Acinetobacter baumannii: emergence of a successful pathogen*. Clinical microbiology reviews, 2008. **21**(3): p. 538-582.
19. de Breij, A., et al., *Do biofilm formation and interactions with human cells explain the clinical success of Acinetobacter baumannii?* PloS one, 2010. **5**(5): p. e10732.
20. Espinal, P., S. Marti, and J. Vila, *Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces*. Journal of Hospital Infection, 2012. **80**(1): p. 56-60.
21. Pourhajibagher, M., et al., *Assessment of biofilm formation among Acinetobacter baumannii strains isolated from burned patients*. Der Pharm. Lett., 2016. **8**: p. 225-229.
22. Momtaz, H., S.M. Seifati, and M. Tavakol, *Determining the prevalence and detection of the most prevalent virulence genes in Acinetobacter baumannii isolated from hospital infections*. International Journal of Medical Laboratory, 2015. **2**(2): p. 87-97.
23. Siau, H., et al., *The epidemiology of acinetobacter infections in Hong Kong*. Journal of medical microbiology, 1996. **44**(5): p. 340-347.
24. AL-Kadmy, I.M., et al., *Molecular characterization of Acinetobacter baumannii isolated from Iraqi hospital environment*. New microbes and new infections, 2018. **21**: p. 51-57.
25. Darvishi, M., *Virulence factors profile and antimicrobial resistance of Acinetobacter baumannii strains isolated from various infections recovered from immunosuppressive patients*. Biomedical and Pharmacology Journal, 2016. **9**(3): p. 1057-1062.
26. Rao, R.S., et al., *Correlation between biofilm production and multiple drug resistance in imipenem resistant clinical isolates of Acinetobacter baumannii*. Indian journal of medical microbiology, 2008. **26**(4): p. 333.
27. Hassan, A., et al., *Evaluation of different detection methods of biofilm formation in the clinical isolates*. Brazilian Journal of Infectious Diseases, 2011. **15**(4): p. 305-311.
28. Dehbalaei, M.A., et al., *Clinical isolates of Acinetobacter baumannii from Tehran hospitals: Pulsed-field gel electrophoresis characterization, clonal lineages, antibiotic susceptibility, and biofilm-forming ability*. Jundishapur Journal of Microbiology, 2017. **10**(7).
29. Abdi-Ali, A., et al., *Assessment of biofilm formation and resistance to imipenem and ciprofloxacin among clinical isolates of Acinetobacter baumannii in Tehran*. Jundishapur journal of microbiology, 2014. **7**(1)